PMID- 26527790
OWN - NLM
STAT- MEDLINE
DCOM- 20160404
LR  - 20210503
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 33
IP  - 35
DP  - 2015 Dec 10
TI  - Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by 
      Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous 
      Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, 
      Placebo-Controlled Study.
PG  - 4202-9
LID - 10.1200/JCO.2015.61.4370 [doi]
AB  - PURPOSE: This multicenter phase III study evaluated the efficacy and safety of 
      lapatinib, an epidermal growth factor receptor/ErbB2 inhibitor, administered 
      concomitantly with chemoradiotherapy and as maintenance monotherapy in patients 
      with high-risk surgically treated squamous cell carcinoma of the head and neck 
      (SCCHN). PATIENTS AND METHODS: Patients with resected stage II to IVA SCCHN, with 
      a surgical margin </= 5 mm and/or extracapsular extension, were randomly assigned 
      to chemoradiotherapy (66 Gy total radiation dose and cisplatin 100 mg/m(2) per 
      day administered on days 1, 22, and 43) plus placebo or lapatinib (1,500 mg per 
      day) before and during chemoradiotherapy, followed by 12 months of maintenance 
      monotherapy. RESULTS: Six hundred eighty-eight patients were enrolled (lapatinib, 
      n = 346; placebo, n = 342). With a median follow-up time of 35.3 months, the 
      study ended early because of the apparent plateauing of disease-free survival 
      (DFS) events. Median DFS assessed by an independent review committee was 53.6 
      months and not reached for lapatinib and placebo, respectively (hazard ratio, 
      1.10; 95% CI, 0.85 to 1.43). Investigator-assessed results confirmed the 
      independent review committee assessment. No significant differences in DFS by 
      human papillomavirus status or overall survival were observed between treatment 
      arms. Similar numbers of patients in both treatment arms experienced adverse 
      events (AEs), with more patients in the lapatinib arm than the placebo arm 
      experiencing serious AEs (48% v 40%, respectively). The most commonly observed 
      treatment-related AEs were diarrhea and rash, both predominantly in the lapatinib 
      arm. CONCLUSION: Addition of lapatinib to chemoradiotherapy and its use as 
      long-term maintenance therapy does not offer any efficacy benefits and had 
      additional toxicity compared with placebo in patients with surgically treated 
      high-risk SCCHN.
CI  - (c) 2015 by American Society of Clinical Oncology.
FAU - Harrington, Kevin
AU  - Harrington K
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Temam, Stephane
AU  - Temam S
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Mehanna, Hisham
AU  - Mehanna H
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - D'Cruz, Anil
AU  - D'Cruz A
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Jain, Minish
AU  - Jain M
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - D'Onofrio, Ida
AU  - D'Onofrio I
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Manikhas, Georgy
AU  - Manikhas G
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Horvath, Zsuzsanna
AU  - Horvath Z
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Sun, Yan
AU  - Sun Y
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Dietzsch, Stefan
AU  - Dietzsch S
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Dubinsky, Pavol
AU  - Dubinsky P
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Holeckova, Petra
AU  - Holeckova P
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - El-Hariry, Iman
AU  - El-Hariry I
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Franklin, Natalie
AU  - Franklin N
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Biswas-Baldwin, Nigel
AU  - Biswas-Baldwin N
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Legenne, Philippe
AU  - Legenne P
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Wissel, Paul
AU  - Wissel P
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Netherway, Thelma
AU  - Netherway T
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Farrell, John
AU  - Farrell J
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Ellis, Catherine
AU  - Ellis C
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Wang-Silvanto, Jing
AU  - Wang-Silvanto J
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Amonkar, Mayur
AU  - Amonkar M
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Ahmed, Nazma
AU  - Ahmed N
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Santillana, Sergio
AU  - Santillana S
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland.
FAU - Bourhis, Jean
AU  - Bourhis J
AD  - Kevin Harrington, Institute of Cancer Research and Royal Marsden Hospital, 
      London; Hisham Mehanna, Institute of Head and Neck Studies and Education, 
      University of Birmingham, Birmingham; Natalie Franklin and John Farrell, 
      GlaxoSmithKline, Uxbridge, United Kingdom; Stephane Temam and Jean Bourhis, 
      Institut Gustave- Roussy, Villejuif; Ida D'Onofrio, Hopital Forcilles, Paris, 
      France; Anil D'Cruz, Tata Memorial Hospital, Mumbai; Minish Jain, Ruby Hall 
      Clinic-Cancer Centre, Pune, India; Georgy Manikhas, St Petersburg City Oncology 
      Dispensary, St Petersburg, Russia; Zsuzsanna Horvath, Szent Imre University 
      Teaching Hospital Budapest, Budapest, Hungary; Yan Sun, Beijing Cancer Hospital, 
      Beijing, China; Stefan Dietzsch, Hospital and Policlinic for Radiation Therapy 
      and Radio-oncology, Leipzig, Germany; Pavol Dubinsky, East Slovakia Cancer 
      Institute, Kosice, Slovakia; Petra Holeckova, Institute of Radiation Oncology, 
      Hospital Na Bulovce, and 1st Medical Faculty of Charles University, Prague, Czech 
      Republic; Iman El-Hariry, Synta Pharmaceutical, Lexington, MA; Paul Wissel and 
      Mayur Amonkar, Novartis Pharmaceuticals, East Hanover, NJ; Catherine Ellis and 
      Sergio Santillana, GlaxoSmithKline, Philadelphia, PA; and Nigel Biswas-Baldwin, 
      Philippe Legenne, Thelma Netherway, Jing Wang-Silvanto, and Nazma Ahmed, Novartis 
      Pharma AG, Basel, Switzerland. jean.bourhis@chuv.ch.
LA  - eng
SI  - ClinicalTrials.gov/NCT00424255
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20151102
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Quinazolines)
RN  - 0VUA21238F (Lapatinib)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - PQX0D8J21J (Cetuximab)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
CIN - J Clin Oncol. 2016 Jun 10;34(17):2072-3. PMID: 27069073
CIN - J Clin Oncol. 2016 Jun 10;34(17):2073-4. PMID: 27069077
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma, Squamous Cell/metabolism/*therapy
MH  - Cetuximab/administration & dosage
MH  - *Chemoradiotherapy
MH  - Chemotherapy, Adjuvant
MH  - Cisplatin/administration & dosage
MH  - Disease-Free Survival
MH  - Dose Fractionation, Radiation
MH  - Double-Blind Method
MH  - ErbB Receptors/drug effects/genetics
MH  - Female
MH  - Head and Neck Neoplasms/metabolism/*therapy
MH  - Humans
MH  - International Cooperation
MH  - Kaplan-Meier Estimate
MH  - Lapatinib
MH  - *Maintenance Chemotherapy
MH  - Male
MH  - Middle Aged
MH  - Molecular Targeted Therapy
MH  - Odds Ratio
MH  - Quinazolines/*therapeutic use
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - Treatment Outcome
EDAT- 2015/11/04 06:00
MHDA- 2016/04/05 06:00
CRDT- 2015/11/04 06:00
PHST- 2015/11/04 06:00 [entrez]
PHST- 2015/11/04 06:00 [pubmed]
PHST- 2016/04/05 06:00 [medline]
AID - JCO.2015.61.4370 [pii]
AID - 10.1200/JCO.2015.61.4370 [doi]
PST - ppublish
SO  - J Clin Oncol. 2015 Dec 10;33(35):4202-9. doi: 10.1200/JCO.2015.61.4370. Epub 2015 
      Nov 2.